^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    aDC1 vaccine

    i
    Other names: aDC1 vaccine, alphaDC1, alpha-type-1 polarized dendritic cells, autologous alpha-DC1/TBVA vaccine, αDC1-TBVA vaccine
    Associations

    News

    Trials
    Company:
    Roswell Park, University of Pittsburgh
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    9d
    Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=19, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: Oct 2026 --> Feb 2027 | Trial primary completion date: Oct 2026 --> Feb 2027
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    Keytruda (pembrolizumab) • aDC1 vaccine
    5ms
    Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines (clinicaltrials.gov)
    P1/2, N=25, Recruiting, Roswell Park Cancer Institute | Suspended --> Recruiting
    Enrollment open • Metastases
    |
    IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • CCL2 (Chemokine (C-C motif) ligand 2) • ITGAM (Integrin, alpha M) • FOXP3 (Forkhead Box P3) • CCL22 (C-C Motif Chemokine Ligand 22) • CCL3 (C-C Motif Chemokine Ligand 3) • ITGAX (Integrin Subunit Alpha X)
    |
    cisplatin • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
    5ms
    Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov)
    P2, N=24, Recruiting, Roswell Park Cancer Institute | Trial completion date: Aug 2025 --> Nov 2025 | Trial primary completion date: Aug 2025 --> Nov 2025
    Trial completion date • Trial primary completion date • Combination therapy • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
    6ms
    Effects of Injectable Solutions on the Quality of Monocyte-Derived Dendritic Cells for Immunotherapy. (PubMed, J Immunol Res)
    Alpha-type-1-polarized dendritic cells (aDC1s) have been shown to induce type-1 immunity with a high capacity to produce interleukin-12p70 (IL-12p70)...Cellular morphology was observed by electron microscopy, and the production of IL-12p70 by aDC1s was evaluated by ELISA. Compared with normal saline, Ringer's lactate solution was more effective at maintaining DC viability for up to 8 hr of incubation at 4 or 22°C.
    Journal
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CSF2 (Colony stimulating factor 2) • IFNA1 (Interferon Alpha 1) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4)
    |
    aDC1 vaccine
    6ms
    Autologous Dendritic Cell Vaccine in Kidney Cancer (clinicaltrials.gov)
    P2, N=42, Recruiting, Jodi Maranchie | Phase classification: P2a --> P2
    Phase classification • Combination therapy
    |
    ER (Estrogen receptor) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • LAMP3 (Lysosomal Associated Membrane Protein 3) • GZMB (Granzyme B) • BTLA (B And T Lymphocyte Associated) • CD31 (Platelet and endothelial cell adhesion molecule 1) • NRP1 (Neuropilin 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • ANXA5 (Annexin A5)
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • aDC1 vaccine
    7ms
    Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov)
    P2, N=24, Recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2025 --> Aug 2025
    Trial completion date • Combination therapy • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
    8ms
    Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=19, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: May 2026 --> Oct 2026 | Trial primary completion date: May 2026 --> Oct 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    Keytruda (pembrolizumab) • aDC1 vaccine
    11ms
    Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov)
    P2, N=24, Recruiting, Roswell Park Cancer Institute | Suspended --> Recruiting
    Enrollment open
    |
    CD8 (cluster of differentiation 8)
    |
    CD8 positive
    |
    Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
    1year
    Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=19, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: Sep 2025 --> Jan 2026 | Trial primary completion date: Sep 2025 --> Jan 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    Keytruda (pembrolizumab) • aDC1 vaccine
    1year
    Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Roswell Park Cancer Institute | N=18 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Immune cell
    |
    CD8 (cluster of differentiation 8)
    |
    aDC1 vaccine
    1year
    Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=18, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: Aug 2025 --> Dec 2025 | Trial primary completion date: Aug 2025 --> Dec 2025
    Trial completion date • Trial primary completion date • Immune cell
    |
    CD8 (cluster of differentiation 8) • NKG2D (killer cell lectin like receptor K1)
    |
    aDC1 vaccine
    1year
    Targeting the pericyte antigen DLK1 with an alpha type-1 polarized dendritic cell vaccine results in tumor vascular modulation and protection against colon cancer progression. (PubMed, Front Immunol)
    Our pre-clinical data demonstrate the αDC1 vaccine's ability to induce anti-tumor effects by facilitating cytotoxic T lymphocyte activity and ablating the tumor vasculature. This work, overall, provides a foundation to further interrogate immune-mediated mechanisms of protection in order to help devise efficacious αDC1-based strategies for patients with CRC.
    Journal
    |
    DLK1 (Delta Like Non-Canonical Notch Ligand 1)
    |
    DLK1 expression
    |
    aDC1 vaccine
    over1year
    Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=19, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: May 2025 --> Sep 2025 | Trial primary completion date: May 2025 --> Sep 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    Keytruda (pembrolizumab) • aDC1 vaccine
    over1year
    Autologous Dendritic Cell Vaccine in Kidney Cancer (clinicaltrials.gov)
    P2a, N=42, Recruiting, Jodi Maranchie | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    CD31 (Platelet and endothelial cell adhesion molecule 1) • HES1 (Hes Family BHLH Transcription Factor 1) • NRP1 (Neuropilin 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • aDC1 vaccine
    over1year
    Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ breast cancer. (ASCO 2023)
    Exploratory endpoints include changes in intratumoral biomarkers (CTLs, PDL1, chemokines) in pre- and post-treatment peripheral tumor biopsies and immune changes in the blood. Clinical trial information: NCT04348747.
    Clinical • P2a data • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CCR5 (C-C Motif Chemokine Receptor 5) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • CXCR3 (C-X-C Motif Chemokine Receptor 3)
    |
    HER-2 overexpression • ERBB3 overexpression • CCR5 expression
    |
    Keytruda (pembrolizumab) • aDC1 vaccine
    over1year
    Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=19, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2025 --> May 2025
    Trial completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    Keytruda (pembrolizumab) • aDC1 vaccine
    almost2years
    Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=19, Not yet recruiting, Roswell Park Cancer Institute | Trial primary completion date: Dec 2024 --> Apr 2025
    Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    Keytruda (pembrolizumab) • aDC1 vaccine
    almost2years
    A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
    P1b, N=0, Withdrawn, Roswell Park Cancer Institute | N=12 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    IFNG (Interferon, gamma)
    |
    aDC1 vaccine
    almost2years
    Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=18, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • Immune cell
    |
    CD8 (cluster of differentiation 8) • NKG2D (killer cell lectin like receptor K1)
    |
    aDC1 vaccine
    2years
    Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients (clinicaltrials.gov)
    P1, N=18, Completed, Joseph Baar, MD, PhD | Trial completion date: Oct 2019 --> Jul 2022
    Trial completion date • Metastases
    |
    IFNG (Interferon, gamma)
    |
    gemcitabine • aDC1 vaccine
    2years
    Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=19, Not yet recruiting, Roswell Park Cancer Institute | Phase classification: P1/2 --> P2
    Phase classification • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    Keytruda (pembrolizumab) • aDC1 vaccine
    2years
    Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines (clinicaltrials.gov)
    P1/2, N=25, Suspended, Roswell Park Cancer Institute | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    cisplatin • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
    over2years
    Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=19, Not yet recruiting, Roswell Park Cancer Institute
    New P1/2 trial • New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    Keytruda (pembrolizumab) • aDC1 vaccine